{"gene":"ARIH1","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2011,"finding":"HHARI (ARIH1) functions as a RING/HECT hybrid E3 ligase: it binds E2 (UBCH7) via its RING1 domain but transfers ubiquitin through an obligate thioester intermediate at a conserved cysteine in the RING2 domain, classifying RBR ligases as mechanistically distinct from canonical RING E3s.","method":"In vitro ubiquitin transfer assays, active-site cysteine mutagenesis, biochemical characterization of E2-E3 pairs","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with active-site mutagenesis establishing obligate thioester mechanism, replicated across RBR family members including HHARI","pmids":["21532592"],"is_preprint":false},{"year":1999,"finding":"HHARI (ARIH1) interacts specifically with UbcH7 and UbcH8 (but not UbcH5 or UbcH1) via its N-terminal RING1 finger motif and IBR domain, identified by yeast two-hybrid screen and confirmed by in vitro binding studies.","method":"Yeast two-hybrid screen, in vitro binding assays (pulldown)","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid plus in vitro binding, single lab, two orthogonal methods","pmids":["10521492"],"is_preprint":false},{"year":2001,"finding":"HHARI (ARIH1) co-localizes with UbcH7 in the perinuclear region of mammalian cells; a minimal interaction region (residues 186–254) was defined, specific amino acid residues essential for the RING1–UbcH7 interaction were identified, and conversion of RING1 from RING-HC to RING-H2 type abolishes interaction.","method":"Co-immunoprecipitation in mammalian cells, co-localization by immunofluorescence, deletion/point mutagenesis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and mutagenesis, single lab, multiple orthogonal methods","pmids":["11278816"],"is_preprint":false},{"year":2013,"finding":"HHARI (ARIH1) and TRIAD1, Ariadne-subfamily RBR ligases, associate with distinct neddylated Cullin-RING ligase (CRL) complexes; neddylated CRL binding greatly stimulates HHARI RBR ligase activity in vitro (auto-ubiquitylation, thioester discharge, ubiquitin-vinyl methyl ester reactivity), and RBR ligase activity reciprocally impacts CRL levels and activities in vivo.","method":"Co-immunoprecipitation, in vitro ubiquitylation assays, ubiquitin-vinyl methyl ester reactivity, genetic (in vivo) CRL activity assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal biochemical methods (auto-ubiquitylation, thioester discharge, activity-based probe) plus genetic in vivo validation, single lab","pmids":["24076655"],"is_preprint":false},{"year":2013,"finding":"The NMR solution structure of the HHARI RING2 domain was determined, revealing two Zn2+-binding sites, a single exposed catalytic cysteine, and a near-mirror-image arrangement of catalytic residues compared to HECT E3 ligase NEDD4, providing structural rationale for the RING/HECT hybrid mechanism.","method":"NMR structure determination, structural comparison with HECT E3 ligases","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — experimental NMR structure with functional interpretation, single lab","pmids":["24058416"],"is_preprint":false},{"year":2015,"finding":"ARIH1 protects cells against genotoxic stress by promoting non-degradative ubiquitination of 4EHP (a competitive eIF4E inhibitor), localizing to perinuclear ribosome-containing regions after DNA damage, and inducing mRNA translation arrest in an ARIH1 ubiquitin-ligase-activity-dependent manner; ATM signaling stabilizes ARIH1 protein by attenuating its proteasomal degradation.","method":"RNAi screen, expression of wild-type vs. ubiquitinase-defective ARIH1 mutants, subcellular fractionation, co-immunoprecipitation (ARIH1–4EHP), mRNA translation assays, cell viability assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (KD with rescue by WT but not catalytic mutant, co-IP, localization, translation assay), single lab","pmids":["25624349"],"is_preprint":false},{"year":2017,"finding":"Crystal/structural studies showed that HHARI RING1 contains a unique Zn2+-loop II extension (not present in canonical RING E3s) that acts as a steric wedge to enforce an open E2~Ub conformation, explaining how RBR RING1 promotes Ub transfer to the E3 active-site cysteine rather than directly to substrate.","method":"X-ray crystallography of HHARI/UbcH7~Ub complex, mutagenesis, biochemical validation","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure combined with biochemical validation, mechanistically explains conformational restriction, single lab","pmids":["28552575"],"is_preprint":false},{"year":2018,"finding":"Drosophila Ari-1 (ortholog of ARIH1) mono-ubiquitinates the LINC complex member Koi, regulating myonuclear positioning; Ari-1 and Parkin are functionally redundant for this process (each rescues the other's mutant phenotype); human ARIH1 rescues fly ari-1 mutants whereas patient-derived ARIH1 variants fail to do so.","method":"Drosophila genetics (loss-of-function, rescue experiments), in vitro/in vivo ubiquitination assays (mono-ubiquitination of Koi), immunofluorescence of LINC complex members","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic epistasis combined with biochemical ubiquitination assay and cross-species rescue, multiple orthogonal approaches","pmids":["29689197"],"is_preprint":false},{"year":2021,"finding":"ARIH1 is the E3 ubiquitin ligase that ubiquitinates PD-L1 following GSK3α-mediated phosphorylation at Ser279/Ser283, targeting PD-L1 for proteasomal degradation; ARIH1 overexpression suppresses tumor growth and promotes cytotoxic T cell activation in immunocompetent but not immunocompromised mice.","method":"Co-immunoprecipitation, ubiquitination assays, ARIH1 overexpression/knockdown in tumor models, in vivo syngeneic tumor experiments, high-throughput drug screen","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and ubiquitination assay plus in vivo functional validation, single lab","pmids":["33879767"],"is_preprint":false},{"year":2022,"finding":"ARIH1 catalyzes mono-ISGylation of cGAS at K187, which promotes cGAS oligomerization and activation, thereby enhancing type I interferon and proinflammatory cytokine production in response to HSV-1 or cytoplasmic DNA; conditional Arih1 knockout mice are hypersensitive to HSV-1 and show reduced autoimmune phenotypes in TREX1-deficient background.","method":"Co-immunoprecipitation, ISGylation assays, ARIH1 KO/KD (siRNA, conditional mouse knockouts), HSV-1 infection models, site-directed mutagenesis (K187)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (biochemical ISGylation assay, mutagenesis at K187, conditional KO mouse models in two cell-type backgrounds), mechanistic and genetic validation converge","pmids":["36217001"],"is_preprint":false},{"year":2022,"finding":"ARIH1 ubiquitinates hnRNP-E1, promoting its degradation and thereby facilitating EMT induction; ARIH1 silencing increases hnRNP-E1 stability and reduces ubiquitination, delays EMT and invasion, while ARIH1 overexpression promotes EMT and invasion; ARIH1 silencing in breast cancer cells reduces cancer stem cell properties in vitro and tumor formation in vivo.","method":"Yeast two-hybrid (interaction identification), ARIH1 KD/OE in mammary epithelial and breast cancer cell lines, ubiquitination assays, miniTurboID proximity labeling, in vivo tumor formation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus ubiquitination assay plus KD/OE functional phenotype, single lab, multiple orthogonal methods","pmids":["35102251"],"is_preprint":false},{"year":2022,"finding":"The HHARI (ARIH1) Rcat (RING2) domain contains a di-aromatic surface that forms a binding platform for substrate recruitment (demonstrated for 4EHP); a phosphomimetic mutation on the auto-inhibitory Ariadne domain promotes Rcat release and reorientation enabling transthiolation and substrate modification, defining a general model for RBR substrate recognition.","method":"XL-MS, HDX-MS, NMR, biochemical binding and ubiquitination assays, phosphomimetic mutagenesis","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple structural/biophysical methods (XL-MS, HDX-MS, NMR) plus biochemical validation and mutagenesis, single lab","pmids":["35716664"],"is_preprint":false},{"year":2023,"finding":"ARIH1 mediates ubiquitination and proteasomal degradation of DNA-PKcs, thereby activating the STING pathway and promoting cytotoxic T cell infiltration; a phospho-mimetic mutant of cGAS (T68E/S213D) blocks this ARIH1-DNA-PKcs-STING signaling axis.","method":"Co-immunoprecipitation, ubiquitination assays, ARIH1 overexpression/knockdown, syngeneic in vivo tumor models, high-throughput drug screen","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and ubiquitination assay with in vivo validation, single lab","pmids":["37429863"],"is_preprint":false},{"year":2023,"finding":"ARIH1 catalyzes serine (oxyester) ubiquitylation in addition to canonical lysine (isopeptide) ubiquitylation on CRL-bound substrates; efficiency of Ser ubiquitylation is highly dependent on local sequence context; comprehensive mutagenesis of the Rcat domain identified residues differentially affecting oxyester vs. isopeptide bond formation.","method":"In vitro reconstitution with purified components, comprehensive active-site mutagenesis of Rcat domain, biochemical ubiquitylation assays measuring Ser vs. Lys ubiquitylation","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with systematic mutagenesis distinguishing Ser vs. Lys ubiquitylation activities, single lab but rigorous biochemistry","pmids":["37870100"],"is_preprint":false},{"year":2023,"finding":"ARIH1 interacts with SQSTM1/p62 and enhances RIG-I stability (via p62-mediated pathway), thereby promoting IFN-β and downstream ISG expression during influenza A virus infection; ARIH1 is upregulated during IAV infection.","method":"Co-immunoprecipitation, Western blot, TCID50 viral titer assay, luciferase reporter assay, siRNA knockdown","journal":"Virology journal","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, co-IP plus reporter assay but mechanism of ARIH1 enzymatic action on RIG-I not directly established","pmids":["37005687"],"is_preprint":false},{"year":2006,"finding":"C. elegans ARI-1 (ARIH1 ortholog) functions as an RBR ubiquitin ligase with UBC-18 (ortholog of UbcH7) to control pharyngeal morphogenesis; genetic interactions show ARI-1 is the principal Ariadne family member for this process, and GFP reporters show dynamic expression in muscles and neurons.","method":"Yeast two-hybrid (ARI-1/UBC-18 interaction), C. elegans genetic analysis (double mutants, RNAi), GFP reporter expression","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in C. elegans plus yeast two-hybrid, multiple orthogonal approaches, single lab","pmids":["16457801"],"is_preprint":false},{"year":2009,"finding":"In C. elegans, UBC-18 (UbcH7 ortholog)–ARI-1 (ARIH1 ortholog) complex acts in ubiquitin-mediated proteolysis to negatively regulate SUP-35 abundance, functioning redundantly with LIN-35/Rb (which acts as a transcriptional repressor of sup-35) to control pharyngeal morphogenesis; genetic suppressor analysis showed sup-35 mutations revert synthetic lethality of ubc-18; pha-1 double mutants.","method":"Genetic epistasis analysis, double/triple mutant analysis, molecular analysis of SUP-35 abundance","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with molecular validation of SUP-35 regulation, single lab, C. elegans ortholog","pmids":["19521497"],"is_preprint":false},{"year":2012,"finding":"HHARI (ARIH1) localizes to both nucleus and cytoplasm, with higher nuclear levels; it co-localizes with Cajal bodies (p80 coilin, NOPP140), PML bodies, and SC35 bodies; ARIH1 knockdown causes reduced proliferation, increased apoptosis, G2 cell cycle arrest, and reduced total cellular RNA levels.","method":"Antibody-based immunofluorescence, RNAi knockdown screen, flow cytometry (cell cycle analysis), RNA quantification","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments with functional KD phenotype, multiple orthogonal readouts, single lab","pmids":["23059369"],"is_preprint":false},{"year":2011,"finding":"HHARI (ARIH1) binds many of the same substrate proteins as parkin (including CDCrel-1, synphilin-1, and CASK) in vitro, forms aggresomes morphologically indistinguishable from parkin-induced aggresomes (microtubule-dependent, containing ubiquitin-proteasome components), and is detected in human Lewy bodies in Parkinson's disease tissue.","method":"In vitro binding assays (pulldown), cell-based aggresome formation assays, immunofluorescence, immunohistochemistry of human brain tissue","journal":"Journal of molecular neuroscience","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, in vitro pulldown plus cell morphology assay; no direct ubiquitination/enzymatic assay of specific substrates","pmids":["21590270"],"is_preprint":false},{"year":2025,"finding":"ARIH1 directly interacts with PHB1 via its RING1+RBR+RING2 domains and catalyzes K63-linked ubiquitination of PHB1 at K186; this modification promotes PHB1 phosphorylation by Akt and mitochondrial translocation of PHB1, maintaining mitochondrial stability and promoting oxidative phosphorylation in colorectal cancer cells.","method":"Co-immunoprecipitation, in vitro ubiquitination assays, site-directed mutagenesis (K186), subcellular fractionation, mitochondrial function assays","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus in vitro ubiquitination with site-directed mutagenesis, single lab","pmids":["40285603"],"is_preprint":false},{"year":2025,"finding":"ARIH1 independently ubiquitinates PD-L1 in vitro (without requiring CRL as scaffold) and also cooperates with CRLs to catalyze PD-L1 ubiquitination; phosphorylation of PD-L1 enhances ubiquitination by disrupting its membrane association (demonstrated using liposomes); NEDD4 family E3s also ubiquitinate PD-L1.","method":"In vitro reconstitution with purified components (ARIH1, CRL3SPOP, NEDD4), liposome-based enzymatic assays, phosphorylation-mimetic mutants","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified components and liposome assays providing mechanistic detail, single lab but rigorous biochemistry","pmids":["40472843"],"is_preprint":false},{"year":2025,"finding":"ARIH1 mediates ubiquitination and degradation of MFN2, promoting mitophagy and endoplasmic reticulum stress in trophoblasts under hypoxia/reoxygenation conditions; ARIH1 inhibition reverses suppressed proliferation/invasion and reduces ROS, and MFN2 inhibition abolishes the protective effects of ARIH1 downregulation.","method":"Co-immunoprecipitation, ubiquitination assays, ARIH1 KD/overexpression, in vivo PE rat model, HTR8 cell hypoxia/reoxygenation model","journal":"FASEB journal","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, co-IP and functional KD assays but mechanistic detail of ubiquitination site on MFN2 not fully established in abstract","pmids":["40960900"],"is_preprint":false},{"year":2025,"finding":"ARIH1 interacts with NCOA4 and promotes its K48-linked ubiquitination and proteasomal degradation, thereby suppressing ferritinophagy and ferroptosis in lung adenocarcinoma; ARIH1 loss results in iron accumulation, lipid peroxidation, glutathione depletion, and ferroptotic cell death.","method":"Co-immunoprecipitation, ubiquitination assays (K48-linkage), cycloheximide chase, siRNA knockdown, ferroptosis marker assays","journal":"Respiratory research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, co-IP plus ubiquitination assay but Tier 3 due to preprint-equivalent methods described in journal abstract without full structural/reconstitution data","pmids":["42169065"],"is_preprint":false},{"year":2025,"finding":"ARIH1 regulates learning and memory in mice by ubiquitinating and promoting degradation of GIRK2 in dorsal hippocampal CaMKII-expressing neurons; ARIH1 deficiency causes GIRK2 upregulation and spatial learning/memory deficits that are rescued by lentiviral ARIH1 restoration or GIRK channel inhibition; selective ARIH1 KD in CaMKII+ (but not PV+ or SST+) neurons recapitulates the memory deficit.","method":"ARIH1 heterozygous knockout mouse model, lentiviral ARIH1 rescue, cell-type-specific ARIH1 knockdown (CaMKII/PV/SST-Cre), ubiquitination assays, Morris water maze, novel object recognition, GIRK channel pharmacology","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO, cell-type-specific KD, lentiviral rescue, and ubiquitination assay converge, preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.03.10.625121"],"is_preprint":true},{"year":2025,"finding":"HHARI (ARIH1) stimulates IFN-β secretion by directly targeting RIG-I in a neddylation-dependent manner; the acidic N-terminal/UBA-like domains of HHARI are essential for this pro-interferon activity and for interaction with neddylated cullins; truncated HHARI containing only the N-terminal domains retains neddylation-dependent interferon signaling; overexpression of cullins 1–5 enhances HHARI-mediated IFN-β secretion.","method":"HHARI truncation mutants, neddylation inhibitor experiments, overexpression of cullins, IFN-β secretion assays, RIG-I interaction studies","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single lab, functional assays with truncation mutants but no structural or reconstitution data; mechanism of direct RIG-I targeting not biochemically reconstituted","pmids":["bio_10.1101_2025.02.01.636034"],"is_preprint":true},{"year":2025,"finding":"ARIH1 loss leads to MAP4 upregulation and microtubule stabilization (increased tubulin acetylation and enhanced spindle organization) in breast cancer cells, sensitizing them to paclitaxel; this identifies ARIH1 as a regulator of microtubule dynamics.","method":"ARIH1 siRNA knockdown in breast cancer cell lines, tubulin acetylation assays, MAP4 protein level measurement, paclitaxel sensitivity assays (viability, colony formation, apoptosis)","journal":"Cancers","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, KD with downstream phenotype readouts but direct ARIH1 ubiquitination of MAP4 not biochemically demonstrated in abstract","pmids":["40075632"],"is_preprint":false},{"year":2025,"finding":"Pyrotinib enhances interaction between ARIH1 and HER2, promoting HER2 ubiquitination and endocytosis leading to lysosomal degradation of HER2 in HER2-positive NSCLC; tumor growth suppression by pyrotinib in vivo is ARIH1-dependent.","method":"Co-immunoprecipitation, ubiquitination assays, LC-MS/MS, in vivo xenograft tumor model with ARIH1 manipulation","journal":"Cellular oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, co-IP and ubiquitination assay plus in vivo pharmacology, but ARIH1 catalytic role on HER2 not reconstituted biochemically","pmids":["41123818"],"is_preprint":false},{"year":2026,"finding":"Sec61β recruits ARIH1 and 4EHP to the mRNA 5' cap to inhibit eIF4E binding, resulting in selective translational repression of ER-targeted (ERpQC substrate) mRNAs during ER stress; Sec61β deficiency causes cytoplasmic aggresome formation due to overproduction of ERpQC substrates, and motor dysfunction in zebrafish that is rescued by exogenous ARIH1 expression.","method":"Co-immunoprecipitation (Sec61β–ARIH1–4EHP complex), mRNA cap-binding assays, Sec61β KD, zebrafish motor behavior rescue by ARIH1 overexpression, proteasome activity assays","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP establishing ternary complex, functional KD, and cross-species rescue, single lab, multiple orthogonal methods","pmids":["41593190"],"is_preprint":false}],"current_model":"ARIH1 (HHARI) is a RING-between-RING (RBR) E3 ubiquitin ligase that operates via a RING/HECT hybrid mechanism—binding its cognate E2 (UbcH7/UBE2L3) through RING1 (with a unique Zn2+-loop II that enforces an open E2~Ub conformation) and transferring ubiquitin via an obligate thioester intermediate at the RING2 active-site cysteine; it is activated by neddylated Cullin-RING ligase complexes, which relieve its autoinhibitory Ariadne domain and reorient the Rcat domain for substrate ubiquitination. ARIH1 ubiquitinates diverse substrates—including PD-L1, cGAS (mono-ISGylation at K187), 4EHP, DNA-PKcs, PHB1 (K63-linked), NCOA4 (K48-linked), MFN2, hnRNP-E1, HER2, and GIRK2—to regulate proteasomal or lysosomal degradation, mRNA translation arrest (via a Sec61β–ARIH1–4EHP complex at the 5' cap), innate immune signaling, nuclear architecture (mono-ubiquitination of the LINC complex component Koi), and ferroptosis suppression, while also catalyzing non-canonical serine (oxyester) ubiquitylation."},"narrative":{"mechanistic_narrative":"ARIH1 (HHARI) is a RING-between-RING (RBR) E3 ubiquitin ligase that operates by a RING/HECT hybrid mechanism: it binds its cognate E2 (UbcH7/UbcH8) through its RING1 domain but transfers ubiquitin via an obligate thioester intermediate at a conserved catalytic cysteine in the RING2 (Rcat) domain, mechanistically distinguishing RBR ligases from canonical RING E3s [PMID:21532592, PMID:10521492]. Structural work explains each step of this cycle—the RING2 fold positions a single exposed catalytic cysteine in a near-mirror image of HECT active sites [PMID:24058416], a unique Zn2+-loop II extension in RING1 acts as a steric wedge that enforces an open E2~Ub conformation favoring transthiolation [PMID:28552575], and the Rcat domain presents a di-aromatic substrate-binding platform whose engagement is gated by release of the autoinhibitory Ariadne domain [PMID:35716664]. ARIH1 is activated by neddylated Cullin-RING ligase (CRL) complexes, which stimulate its ligase activity and couple it to CRL-bound substrates [PMID:24076655], and it can catalyze non-canonical serine (oxyester) ubiquitylation in addition to canonical lysine isopeptide linkages [PMID:37870100]. Through this chemistry ARIH1 modifies a broad substrate repertoire to control distinct cellular outcomes: it ubiquitinates 4EHP to drive translational arrest under genotoxic stress and, with Sec61β, assembles a 5' cap complex that selectively represses ER-targeted mRNA translation during ER stress [PMID:25624349, PMID:41593190]; it promotes proteasomal degradation of phosphorylated PD-L1 and of DNA-PKcs to enhance antitumor immunity [PMID:33879767, PMID:37429863]; it mono-ISGylates cGAS at K187 to potentiate innate immune signaling [PMID:36217001]; and it mono-ubiquitinates the LINC-complex protein Koi to regulate nuclear positioning, a function shared and rescued across species [PMID:29689197]. Patient-derived ARIH1 variants fail to rescue this conserved activity, linking the protein to developmental phenotypes [PMID:29689197].","teleology":[{"year":1999,"claim":"Establishing which E2 enzymes ARIH1 partners with defined the first step of its catalytic cycle and the specificity of RBR ligases.","evidence":"Yeast two-hybrid screen and in vitro binding assays mapping RING1/IBR interaction with UbcH7 and UbcH8","pmids":["10521492"],"confidence":"Medium","gaps":["Did not establish the catalytic mechanism of ubiquitin transfer","No substrate identified"]},{"year":2001,"claim":"Defining the minimal RING1-UbcH7 interaction surface and its requirement for a RING-HC architecture connected E2 selectivity to a structural determinant.","evidence":"Reciprocal co-IP, immunofluorescence co-localization, and point mutagenesis in mammalian cells","pmids":["11278816"],"confidence":"Medium","gaps":["Functional consequence of perinuclear localization not addressed","Did not link binding to catalytic output"]},{"year":2011,"claim":"Resolving how ARIH1 transfers ubiquitin reclassified it as a RING/HECT hybrid, answering whether RBR ligases use direct E2-to-substrate transfer or an enzyme thioester intermediate.","evidence":"In vitro ubiquitin transfer assays with active-site cysteine mutagenesis across RBR family members","pmids":["21532592"],"confidence":"High","gaps":["Did not explain how the open E2~Ub conformation is enforced","Physiological substrates and activation unknown"]},{"year":2013,"claim":"Discovery that neddylated CRLs bind and stimulate ARIH1 placed the enzyme into the cullin pathway and explained how a basally autoinhibited ligase is activated.","evidence":"Co-IP, in vitro auto-ubiquitylation, thioester discharge, activity-based probe reactivity, and in vivo CRL activity assays","pmids":["24076655"],"confidence":"High","gaps":["Structural basis of CRL-mediated activation not resolved","Substrate range conferred by CRLs not defined"]},{"year":2013,"claim":"The RING2 NMR structure provided the structural rationale for the HECT-like catalytic cysteine arrangement.","evidence":"NMR solution structure of the HHARI RING2 domain with comparison to HECT ligase NEDD4","pmids":["24058416"],"confidence":"High","gaps":["Did not capture the active conformation in context of full-length ligase","Substrate-binding surface not defined"]},{"year":2015,"claim":"Identifying 4EHP ubiquitination as a non-degradative output linked ARIH1 to translational control during genotoxic stress, extending its role beyond proteasomal targeting.","evidence":"RNAi with WT vs. catalytic-mutant rescue, ARIH1-4EHP co-IP, subcellular fractionation, and mRNA translation/viability assays","pmids":["25624349"],"confidence":"Medium","gaps":["Ubiquitination site on 4EHP and chain type not defined","Mechanism of ATM-mediated ARIH1 stabilization not detailed"]},{"year":2017,"claim":"Capturing the HHARI/UbcH7~Ub complex explained how RING1 promotes transthiolation rather than direct substrate ubiquitination.","evidence":"X-ray crystallography of the HHARI/UbcH7~Ub complex with mutagenesis and biochemical validation","pmids":["28552575"],"confidence":"High","gaps":["Did not address substrate recruitment to RING2","Activation by CRLs not structurally integrated"]},{"year":2018,"claim":"Demonstrating that the conserved ortholog mono-ubiquitinates the LINC protein Koi defined a developmental, nuclear-positioning function and connected ARIH1 variants to phenotype via cross-species rescue.","evidence":"Drosophila loss-of-function and rescue genetics, ubiquitination assays, and immunofluorescence of LINC members","pmids":["29689197"],"confidence":"High","gaps":["Specific human disease entity not delineated in this work","Whether Koi-equivalent regulation occurs in mammalian cells not shown"]},{"year":2021,"claim":"Identifying ARIH1 as the E3 for phosphorylated PD-L1 connected it to immune checkpoint regulation and antitumor immunity.","evidence":"Co-IP, ubiquitination assays, ARIH1 OE/KD in tumor models, syngeneic in vivo experiments, and drug screen","pmids":["33879767"],"confidence":"Medium","gaps":["Dependence on CRL scaffolding not resolved here","Direct vs. indirect catalysis not biochemically isolated"]},{"year":2022,"claim":"Discovery that ARIH1 mono-ISGylates cGAS at K187 established a non-ubiquitin modification activity driving innate immune activation.","evidence":"ISGylation assays, K187 mutagenesis, conditional Arih1 KO mice, and HSV-1/TREX1-deficient models","pmids":["36217001"],"confidence":"High","gaps":["Structural basis for ISG15 vs. ubiquitin transfer not defined","How substrate choice between modifications is determined unknown"]},{"year":2022,"claim":"Defining the di-aromatic Rcat substrate platform and Ariadne-release gating produced a general model for how RBR ligases recruit and modify substrates.","evidence":"XL-MS, HDX-MS, NMR, and biochemical binding/ubiquitination assays with phosphomimetic mutagenesis","pmids":["35716664"],"confidence":"High","gaps":["The physiological kinase relieving Ariadne autoinhibition not identified","Generality across all substrates not tested"]},{"year":2022,"claim":"Showing ARIH1-mediated degradation of hnRNP-E1 linked the ligase to EMT and cancer stemness.","evidence":"Yeast two-hybrid, KD/OE in mammary cells, ubiquitination assays, miniTurboID, and in vivo tumor assays","pmids":["35102251"],"confidence":"Medium","gaps":["Ubiquitination site and chain type on hnRNP-E1 not defined","CRL dependence not established"]},{"year":2023,"claim":"Identifying DNA-PKcs as an ARIH1 degradation substrate connected the ligase to STING-pathway activation and T cell infiltration.","evidence":"Co-IP, ubiquitination assays, ARIH1 OE/KD, syngeneic tumor models, and drug screen","pmids":["37429863"],"confidence":"Medium","gaps":["Direct catalysis vs. CRL recruitment not separated","Ubiquitination site on DNA-PKcs not mapped"]},{"year":2023,"claim":"Demonstrating serine (oxyester) ubiquitylation expanded the chemical repertoire of ARIH1 beyond lysine isopeptide bonds and identified active-site residues controlling linkage chemistry.","evidence":"In vitro reconstitution with purified components and comprehensive Rcat-domain mutagenesis comparing Ser vs. Lys ubiquitylation","pmids":["37870100"],"confidence":"High","gaps":["Physiological substrates of Ser ubiquitylation not identified","Cellular relevance of oxyester linkages not established"]},{"year":2025,"claim":"Reconstitution showed ARIH1 can ubiquitinate PD-L1 both independently and cooperatively with CRLs, and that substrate phosphorylation/membrane disengagement controls modification.","evidence":"In vitro reconstitution with purified ARIH1/CRL3SPOP/NEDD4 and liposome-based phosphomimetic assays","pmids":["40472843"],"confidence":"High","gaps":["Relative contribution of CRL-dependent vs. independent activity in cells unknown","Cellular determinants of PD-L1 phosphorylation not addressed"]},{"year":2025,"claim":"Identifying K63-linked ubiquitination of PHB1 connected ARIH1 to mitochondrial function via a non-degradative signal in colorectal cancer.","evidence":"Co-IP, in vitro ubiquitination, K186 mutagenesis, subcellular fractionation, and mitochondrial function assays","pmids":["40285603"],"confidence":"Medium","gaps":["How K63 linkage drives Akt phosphorylation of PHB1 mechanistically unclear","CRL involvement not tested"]},{"year":2025,"claim":"Mouse genetics tied ARIH1-mediated degradation of GIRK2 to learning and memory in hippocampal CaMKII neurons.","evidence":"Heterozygous KO, cell-type-specific KD, lentiviral rescue, ubiquitination assays, and behavioral testing (preprint)","pmids":["bio_10.1101_2025.03.10.625121"],"confidence":"Medium","gaps":["Not yet peer-reviewed","Ubiquitination site on GIRK2 not mapped","Direct catalysis vs. indirect regulation not isolated"]},{"year":2026,"claim":"Defining the Sec61β-ARIH1-4EHP cap complex revealed how ARIH1 imposes selective translational repression of ER-targeted mRNAs during ER stress.","evidence":"Co-IP of the ternary complex, cap-binding assays, Sec61β KD, and ARIH1-rescued zebrafish motor phenotypes","pmids":["41593190"],"confidence":"Medium","gaps":["Whether ARIH1 catalytic activity is required for repression not isolated here","Substrate of ubiquitination within the complex not defined"]},{"year":null,"claim":"How ARIH1 selects among its many substrates and chooses between ubiquitin, ISG15, lysine vs. serine modification, and degradative vs. non-degradative chain types in a given cellular context remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking CRL identity to substrate choice","Physiological signals gating Ariadne autoinhibition release not mapped","Determinants of modification chemistry (Ub vs. ISG15, Lys vs. Ser) in cells unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,8,9,13]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[0,3,6,11,13]},{"term_id":"GO:0031386","term_label":"protein tag activity","supporting_discovery_ids":[9]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[17]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,3,8,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,9,12]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[5,27]}],"complexes":["Sec61β–ARIH1–4EHP cap complex","neddylated Cullin-RING ligase (CRL) complex"],"partners":["UBE2L3","CUL1","PHB1","NCOA4","SQSTM1","SEC61B","4EHP","MFN2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y4X5","full_name":"E3 ubiquitin-protein ligase ARIH1","aliases":["H7-AP2","HHARI","Monocyte protein 6","MOP-6","Protein ariadne-1 homolog","ARI-1","UbcH7-binding protein","UbcM4-interacting protein","Ubiquitin-conjugating enzyme E2-binding protein 1"],"length_aa":557,"mass_kda":64.1,"function":"E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin-conjugating enzyme E2 UBE2L3 (PubMed:15236971, PubMed:21532592, PubMed:23707686, PubMed:24076655, PubMed:27565346). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-RING ubiquitin ligase (CRL) complexes and initiating ubiquitination of CRL substrates: associates with CRL complexes and specifically mediates addition of the first ubiquitin on CRLs targets (PubMed:27565346). The initial ubiquitin is then elongated by CDC34/UBE2R1 and UBE2R2 (PubMed:27565346). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated cullin-RING ubiquitin ligase complexes (PubMed:24076655, PubMed:27565346). Plays a role in protein translation in response to DNA damage by mediating ubiquitination of EIF4E2, the consequences of EIF4E2 ubiquitination are however unclear (PubMed:25624349). According to a report, EIF4E2 ubiquitination leads to promote EIF4E2 cap-binding and protein translation arrest (PubMed:25624349). According to another report EIF4E2 ubiquitination leads to its subsequent degradation (PubMed:14623119). Acts as the ligase involved in ISGylation of EIF4E2 (PubMed:17289916). In vitro, controls the degradation of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex member SUN2 and may therefore have a role in the formation and localization of the LINC complex, and as a consequence, nuclear subcellular localization and nuclear morphology (PubMed:29689197)","subcellular_location":"Cytoplasm; Nucleus; Nucleus, Cajal body","url":"https://www.uniprot.org/uniprotkb/Q9Y4X5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/ARIH1","classification":"Common Essential","n_dependent_lines":1187,"n_total_lines":1208,"dependency_fraction":0.9826158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ARIH1","total_profiled":1310},"omim":[{"mim_id":"605624","title":"ARIADNE RBR E3 UBIQUITIN PROTEIN LIGASE 1; ARIH1","url":"https://www.omim.org/entry/605624"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":44.9},{"tissue":"testis","ntpm":39.7}],"url":"https://www.proteinatlas.org/search/ARIH1"},"hgnc":{"alias_symbol":["HARI","HHARI","UBCH7BP","ARI"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y4X5","domains":[{"cath_id":"3.30.40.10","chopping":"109-165_183-271","consensus_level":"medium","plddt":90.209,"start":109,"end":271},{"cath_id":"1.20.120.1750","chopping":"316-548","consensus_level":"high","plddt":90.8474,"start":316,"end":548}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y4X5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y4X5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y4X5-F1-predicted_aligned_error_v6.png","plddt_mean":80.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARIH1","jax_strain_url":"https://www.jax.org/strain/search?query=ARIH1"},"sequence":{"accession":"Q9Y4X5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y4X5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y4X5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y4X5"}},"corpus_meta":[{"pmid":"21532592","id":"PMC_21532592","title":"UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21532592","citation_count":461,"is_preprint":false},{"pmid":"18611526","id":"PMC_18611526","title":"ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii.","date":"1993","source":"International journal of antimicrobial agents","url":"https://pubmed.ncbi.nlm.nih.gov/18611526","citation_count":176,"is_preprint":false},{"pmid":"10602749","id":"PMC_10602749","title":"Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92.","date":"2000","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/10602749","citation_count":175,"is_preprint":false},{"pmid":"33010231","id":"PMC_33010231","title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33010231","citation_count":131,"is_preprint":false},{"pmid":"32528460","id":"PMC_32528460","title":"Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32528460","citation_count":114,"is_preprint":false},{"pmid":"33879767","id":"PMC_33879767","title":"ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33879767","citation_count":102,"is_preprint":false},{"pmid":"10521492","id":"PMC_10521492","title":"The ubiquitin-conjugating enzymes UbcH7 and UbcH8 interact with RING finger/IBR motif-containing domains of HHARI and H7-AP1.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10521492","citation_count":101,"is_preprint":false},{"pmid":"24076655","id":"PMC_24076655","title":"TRIAD1 and HHARI bind to and are activated by distinct neddylated Cullin-RING ligase complexes.","date":"2013","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/24076655","citation_count":97,"is_preprint":false},{"pmid":"24498911","id":"PMC_24498911","title":"An evaluation of genotyping by sequencing (GBS) to map the Breviaristatum-e (ari-e) locus in cultivated barley.","date":"2014","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24498911","citation_count":84,"is_preprint":false},{"pmid":"11278816","id":"PMC_11278816","title":"Features of the parkin/ariadne-like ubiquitin ligase, HHARI, that regulate its interaction with the ubiquitin-conjugating enzyme, Ubch7.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278816","citation_count":69,"is_preprint":false},{"pmid":"26291793","id":"PMC_26291793","title":"Evidence for a Common Origin of Blacksmiths and Cultivators in the Ethiopian Ari within the Last 4500 Years: Lessons for Clustering-Based Inference.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26291793","citation_count":66,"is_preprint":false},{"pmid":"36217001","id":"PMC_36217001","title":"The E3 ubiquitin ligase ARIH1 promotes antiviral immunity and autoimmunity by inducing mono-ISGylation and oligomerization of cGAS.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36217001","citation_count":60,"is_preprint":false},{"pmid":"37429863","id":"PMC_37429863","title":"ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37429863","citation_count":49,"is_preprint":false},{"pmid":"28552575","id":"PMC_28552575","title":"Structural Studies of HHARI/UbcH7∼Ub Reveal Unique E2∼Ub Conformational Restriction by RBR RING1.","date":"2017","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/28552575","citation_count":48,"is_preprint":false},{"pmid":"35046545","id":"PMC_35046545","title":"The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001.","date":"2022","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/35046545","citation_count":47,"is_preprint":false},{"pmid":"8835917","id":"PMC_8835917","title":"Nerve fiber regeneration following axotomy in the diabetic biobreeding Worcester rat: the effect of ARI treatment.","date":"1996","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/8835917","citation_count":42,"is_preprint":false},{"pmid":"29689197","id":"PMC_29689197","title":"Ari-1 Regulates Myonuclear Organization Together with Parkin and Is Associated with Aortic Aneurysms.","date":"2018","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/29689197","citation_count":41,"is_preprint":false},{"pmid":"31125641","id":"PMC_31125641","title":"Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31125641","citation_count":39,"is_preprint":false},{"pmid":"10395066","id":"PMC_10395066","title":"Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: p53-independent mechanism of action.","date":"1999","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10395066","citation_count":36,"is_preprint":false},{"pmid":"25624349","id":"PMC_25624349","title":"The E3 ubiquitin ligase ARIH1 protects against genotoxic stress by initiating a 4EHP-mediated mRNA translation arrest.","date":"2015","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25624349","citation_count":35,"is_preprint":false},{"pmid":"34476985","id":"PMC_34476985","title":"Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001.","date":"2021","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34476985","citation_count":34,"is_preprint":false},{"pmid":"35102251","id":"PMC_35102251","title":"The ubiquitin E3 ligase ARIH1 regulates hnRNP E1 protein stability, EMT and breast cancer progression.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35102251","citation_count":31,"is_preprint":false},{"pmid":"32028176","id":"PMC_32028176","title":"Ventilation and laboratory confirmed acute respiratory infection (ARI) rates in college residence halls in College Park, Maryland.","date":"2020","source":"Environment international","url":"https://pubmed.ncbi.nlm.nih.gov/32028176","citation_count":31,"is_preprint":false},{"pmid":"2110085","id":"PMC_2110085","title":"Diabetic autonomic neuropathy in BB rats and effect of ARI treatment on heart-rate variability and vagus nerve structure.","date":"1990","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/2110085","citation_count":29,"is_preprint":false},{"pmid":"16457801","id":"PMC_16457801","title":"ARI-1, an RBR family ubiquitin-ligase, functions with UBC-18 to regulate pharyngeal development in C. elegans.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16457801","citation_count":27,"is_preprint":false},{"pmid":"35174095","id":"PMC_35174095","title":"Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35174095","citation_count":24,"is_preprint":false},{"pmid":"19830404","id":"PMC_19830404","title":"Identification and genomic location of a reniform nematode (Rotylenchulus reniformis) resistance locus (Ren ari) introgressed from Gossypium aridum into upland cotton (G. hirsutum).","date":"2009","source":"TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik","url":"https://pubmed.ncbi.nlm.nih.gov/19830404","citation_count":24,"is_preprint":false},{"pmid":"36275777","id":"PMC_36275777","title":"Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36275777","citation_count":23,"is_preprint":false},{"pmid":"23059369","id":"PMC_23059369","title":"Human Homolog of Drosophila Ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies.","date":"2012","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/23059369","citation_count":22,"is_preprint":false},{"pmid":"19521497","id":"PMC_19521497","title":"A mechanistic basis for the coordinated regulation of pharyngeal morphogenesis in Caenorhabditis elegans by LIN-35/Rb and UBC-18-ARI-1.","date":"2009","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19521497","citation_count":22,"is_preprint":false},{"pmid":"33764535","id":"PMC_33764535","title":"Reply to the commentary by Ben-Ari and Delpire: Bumetanide and neonatal seizures: Fiction versus reality.","date":"2021","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/33764535","citation_count":19,"is_preprint":false},{"pmid":"35253928","id":"PMC_35253928","title":"Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.","date":"2022","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35253928","citation_count":19,"is_preprint":false},{"pmid":"30883989","id":"PMC_30883989","title":"5-ARI induces autophagy of prostate epithelial cells through suppressing IGF-1 expression in prostate fibroblasts.","date":"2019","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/30883989","citation_count":19,"is_preprint":false},{"pmid":"27635163","id":"PMC_27635163","title":"Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.","date":"2016","source":"Journal of ultrasound","url":"https://pubmed.ncbi.nlm.nih.gov/27635163","citation_count":18,"is_preprint":false},{"pmid":"21590270","id":"PMC_21590270","title":"The parkin-like human homolog of Drosophila ariadne-1 (HHARI) can induce aggresome formation in mammalian cells and is immunologically detectable in Lewy bodies.","date":"2011","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/21590270","citation_count":15,"is_preprint":false},{"pmid":"27835941","id":"PMC_27835941","title":"Marker development using SLAF-seq and whole-genome shotgun strategy to fine-map the semi-dwarf gene ari-e in barley.","date":"2016","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27835941","citation_count":15,"is_preprint":false},{"pmid":"7821191","id":"PMC_7821191","title":"Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.","date":"1994","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/7821191","citation_count":15,"is_preprint":false},{"pmid":"24058416","id":"PMC_24058416","title":"Structure of the HHARI catalytic domain shows glimpses of a HECT E3 ligase.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24058416","citation_count":14,"is_preprint":false},{"pmid":"29050976","id":"PMC_29050976","title":"Evolution in situ of ARI-A in pB2-1, a type 1 IncC plasmid recovered from Klebsiella pneumoniae, and stability of Tn4352B.","date":"2017","source":"Plasmid","url":"https://pubmed.ncbi.nlm.nih.gov/29050976","citation_count":14,"is_preprint":false},{"pmid":"37905734","id":"PMC_37905734","title":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.","date":"2023","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/37905734","citation_count":13,"is_preprint":false},{"pmid":"28707514","id":"PMC_28707514","title":"Removal of estrone, 17β-estradiol, and estriol from sewage and cow dung by immobilized Novosphingobium sp. ARI-1.","date":"2017","source":"Environmental technology","url":"https://pubmed.ncbi.nlm.nih.gov/28707514","citation_count":13,"is_preprint":false},{"pmid":"35716664","id":"PMC_35716664","title":"Cullin-independent recognition of HHARI substrates by a dynamic RBR catalytic domain.","date":"2022","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/35716664","citation_count":12,"is_preprint":false},{"pmid":"27318267","id":"PMC_27318267","title":"pDGO100, a type 1 IncC plasmid from 1981 carrying ARI-A and a Tn1696-like transposon in a novel integrating element.","date":"2016","source":"Plasmid","url":"https://pubmed.ncbi.nlm.nih.gov/27318267","citation_count":11,"is_preprint":false},{"pmid":"37870100","id":"PMC_37870100","title":"Catalysis of non-canonical protein ubiquitylation by the ARIH1 ubiquitin ligase.","date":"2023","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/37870100","citation_count":8,"is_preprint":false},{"pmid":"37005687","id":"PMC_37005687","title":"ARIH1 inhibits influenza A virus replication and facilitates RIG-I dependent immune signaling by interacting with SQSTM1/p62.","date":"2023","source":"Virology journal","url":"https://pubmed.ncbi.nlm.nih.gov/37005687","citation_count":5,"is_preprint":false},{"pmid":"41106484","id":"PMC_41106484","title":"International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI).","date":"2025","source":"Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/41106484","citation_count":5,"is_preprint":false},{"pmid":"40285603","id":"PMC_40285603","title":"The E3 Ubiquitin Ligase ARIH1 Facilitates Colorectal Cancer Progression by Promoting Oxidative Phosphorylation via the Mitochondrial Translocation of K63-Linked Ubiquitinated PHB1.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40285603","citation_count":4,"is_preprint":false},{"pmid":"40255936","id":"PMC_40255936","title":"Genetic dissection of the interactions between semi-dwarfing genes sdw1 and ari-e and their effects on agronomic traits in a barley MAGIC population.","date":"2020","source":"Molecular breeding : new strategies in plant improvement","url":"https://pubmed.ncbi.nlm.nih.gov/40255936","citation_count":4,"is_preprint":false},{"pmid":"38252354","id":"PMC_38252354","title":"Epidemic profile of common respiratory viruses in association SARS CoV-2 among SARI and ARI-two year study.","date":"2024","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/38252354","citation_count":4,"is_preprint":false},{"pmid":"40260169","id":"PMC_40260169","title":"Molecular epidemiological characterization of human bocavirus (HBoV) in acute respiratory infection (ARI) patients in Yucheng, China.","date":"2025","source":"Frontiers in public health","url":"https://pubmed.ncbi.nlm.nih.gov/40260169","citation_count":4,"is_preprint":false},{"pmid":"40075632","id":"PMC_40075632","title":"ARIH1 Inhibition Promotes Microtubule Stability and Sensitizes Breast Cancer Cells to Microtubule-Stabilizing Agents.","date":"2025","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/40075632","citation_count":3,"is_preprint":false},{"pmid":"35993470","id":"PMC_35993470","title":"CADD Studies in the Discovery of Potential ARI (Aldose Reductase Inhibitors) Agents for the Treatment of Diabetic Complications.","date":"2023","source":"Current diabetes reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35993470","citation_count":3,"is_preprint":false},{"pmid":"3223136","id":"PMC_3223136","title":"Lectins and their role in a new polyvalent bacterial vaccine against ARI.","date":"1988","source":"Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/3223136","citation_count":3,"is_preprint":false},{"pmid":"28821533","id":"PMC_28821533","title":"Salmonella ubiquitination: ARIH1 enters the fray.","date":"2017","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/28821533","citation_count":2,"is_preprint":false},{"pmid":"40472843","id":"PMC_40472843","title":"Biochemical analysis of PD-L1 ubiquitination by CRL3SPOP, ARIH1, and NEDD4 family ubiquitin ligases.","date":"2025","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/40472843","citation_count":2,"is_preprint":false},{"pmid":"1656713","id":"PMC_1656713","title":"Peripheral nerve repair following ARI treatment.","date":"1991","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/1656713","citation_count":2,"is_preprint":false},{"pmid":"40987492","id":"PMC_40987492","title":"T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes.","date":"2025","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40987492","citation_count":1,"is_preprint":false},{"pmid":"26827319","id":"PMC_26827319","title":"A novel laser-induced fluorescence scheme for Ar-I in a plasma.","date":"2016","source":"The Review of scientific instruments","url":"https://pubmed.ncbi.nlm.nih.gov/26827319","citation_count":1,"is_preprint":false},{"pmid":"40960900","id":"PMC_40960900","title":"ARIH1 Promotes Preeclampsia by Inducing MFN2-Dependent Hypoxia-Triggered Mitophagy and Endoplasmic Reticulum Stress in Trophoblasts.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40960900","citation_count":0,"is_preprint":false},{"pmid":"41123818","id":"PMC_41123818","title":"Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2.","date":"2025","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/41123818","citation_count":0,"is_preprint":false},{"pmid":"42256546","id":"PMC_42256546","title":"Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.","date":"2026","source":"HemaSphere","url":"https://pubmed.ncbi.nlm.nih.gov/42256546","citation_count":0,"is_preprint":false},{"pmid":"42169065","id":"PMC_42169065","title":"Single-cell N4-acetylcytidine regulatory landscape identifies ARIH1 as a ferroptosis-suppressive oncogenic driver in lung adenocarcinoma.","date":"2026","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/42169065","citation_count":0,"is_preprint":false},{"pmid":"27528653","id":"PMC_27528653","title":"Hari Shroff: Taking a closer look.","date":"2016","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27528653","citation_count":0,"is_preprint":false},{"pmid":"23747110","id":"PMC_23747110","title":"HHARI is one HECT of a RING.","date":"2013","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/23747110","citation_count":0,"is_preprint":false},{"pmid":"41593190","id":"PMC_41593190","title":"Sec61β maintains cytoplasmic proteostasis via ARIH1-mediated translational repression upon ER stress.","date":"2026","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/41593190","citation_count":0,"is_preprint":false},{"pmid":"38337909","id":"PMC_38337909","title":"Determination of the Allelic Composition of the sdw1/denso (HvGA20ox2), uzu1 (HvBRI1) and ari-e (HvDep1) Genes in Spring Barley Accessions from the VIR Collection.","date":"2024","source":"Plants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38337909","citation_count":0,"is_preprint":false},{"pmid":"40223852","id":"PMC_40223852","title":"Analysis of Gene Polymorphisms in Benign Prostate Hyperplasia Patients Receiving Combination Therapy of Alpha Blocker (a-Blocker) and 5-Alpha Reductase Inhibitor (5-ARI).","date":"2025","source":"Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH","url":"https://pubmed.ncbi.nlm.nih.gov/40223852","citation_count":0,"is_preprint":false},{"pmid":"42169809","id":"PMC_42169809","title":"Wild barley cytoplasms reduce grain weight plasticity, with environment-dependent cytonuclear epistasis at the ari-e locus.","date":"2026","source":"Molecular breeding : new strategies in plant improvement","url":"https://pubmed.ncbi.nlm.nih.gov/42169809","citation_count":0,"is_preprint":false},{"pmid":"25272843","id":"PMC_25272843","title":"[Optimization of hydrolysis process of linarin using response surface methodology and research about ARI activity of glycosylation-acacetin].","date":"2014","source":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","url":"https://pubmed.ncbi.nlm.nih.gov/25272843","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.01.636034","title":"The acidic N-terminus of HHARI and neddylation are essential for the activation and maintenance of RIG-I-mediated type I interferon response","date":"2025-02-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.01.636034","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.10.625121","title":"ARIH1 deficiency impairs spatial learning and memory via GIRK2 upregulation in hippocampal CaMKII-expressing neurons in mice","date":"2025-03-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.10.625121","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":36314,"output_tokens":7429,"usd":0.110188,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16664,"output_tokens":5348,"usd":0.10851,"stage2_stop_reason":"end_turn"},"total_usd":0.218698,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"HHARI (ARIH1) functions as a RING/HECT hybrid E3 ligase: it binds E2 (UBCH7) via its RING1 domain but transfers ubiquitin through an obligate thioester intermediate at a conserved cysteine in the RING2 domain, classifying RBR ligases as mechanistically distinct from canonical RING E3s.\",\n      \"method\": \"In vitro ubiquitin transfer assays, active-site cysteine mutagenesis, biochemical characterization of E2-E3 pairs\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with active-site mutagenesis establishing obligate thioester mechanism, replicated across RBR family members including HHARI\",\n      \"pmids\": [\"21532592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HHARI (ARIH1) interacts specifically with UbcH7 and UbcH8 (but not UbcH5 or UbcH1) via its N-terminal RING1 finger motif and IBR domain, identified by yeast two-hybrid screen and confirmed by in vitro binding studies.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro binding assays (pulldown)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid plus in vitro binding, single lab, two orthogonal methods\",\n      \"pmids\": [\"10521492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"HHARI (ARIH1) co-localizes with UbcH7 in the perinuclear region of mammalian cells; a minimal interaction region (residues 186–254) was defined, specific amino acid residues essential for the RING1–UbcH7 interaction were identified, and conversion of RING1 from RING-HC to RING-H2 type abolishes interaction.\",\n      \"method\": \"Co-immunoprecipitation in mammalian cells, co-localization by immunofluorescence, deletion/point mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and mutagenesis, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"11278816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HHARI (ARIH1) and TRIAD1, Ariadne-subfamily RBR ligases, associate with distinct neddylated Cullin-RING ligase (CRL) complexes; neddylated CRL binding greatly stimulates HHARI RBR ligase activity in vitro (auto-ubiquitylation, thioester discharge, ubiquitin-vinyl methyl ester reactivity), and RBR ligase activity reciprocally impacts CRL levels and activities in vivo.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitylation assays, ubiquitin-vinyl methyl ester reactivity, genetic (in vivo) CRL activity assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal biochemical methods (auto-ubiquitylation, thioester discharge, activity-based probe) plus genetic in vivo validation, single lab\",\n      \"pmids\": [\"24076655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The NMR solution structure of the HHARI RING2 domain was determined, revealing two Zn2+-binding sites, a single exposed catalytic cysteine, and a near-mirror-image arrangement of catalytic residues compared to HECT E3 ligase NEDD4, providing structural rationale for the RING/HECT hybrid mechanism.\",\n      \"method\": \"NMR structure determination, structural comparison with HECT E3 ligases\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — experimental NMR structure with functional interpretation, single lab\",\n      \"pmids\": [\"24058416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ARIH1 protects cells against genotoxic stress by promoting non-degradative ubiquitination of 4EHP (a competitive eIF4E inhibitor), localizing to perinuclear ribosome-containing regions after DNA damage, and inducing mRNA translation arrest in an ARIH1 ubiquitin-ligase-activity-dependent manner; ATM signaling stabilizes ARIH1 protein by attenuating its proteasomal degradation.\",\n      \"method\": \"RNAi screen, expression of wild-type vs. ubiquitinase-defective ARIH1 mutants, subcellular fractionation, co-immunoprecipitation (ARIH1–4EHP), mRNA translation assays, cell viability assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (KD with rescue by WT but not catalytic mutant, co-IP, localization, translation assay), single lab\",\n      \"pmids\": [\"25624349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal/structural studies showed that HHARI RING1 contains a unique Zn2+-loop II extension (not present in canonical RING E3s) that acts as a steric wedge to enforce an open E2~Ub conformation, explaining how RBR RING1 promotes Ub transfer to the E3 active-site cysteine rather than directly to substrate.\",\n      \"method\": \"X-ray crystallography of HHARI/UbcH7~Ub complex, mutagenesis, biochemical validation\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure combined with biochemical validation, mechanistically explains conformational restriction, single lab\",\n      \"pmids\": [\"28552575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Drosophila Ari-1 (ortholog of ARIH1) mono-ubiquitinates the LINC complex member Koi, regulating myonuclear positioning; Ari-1 and Parkin are functionally redundant for this process (each rescues the other's mutant phenotype); human ARIH1 rescues fly ari-1 mutants whereas patient-derived ARIH1 variants fail to do so.\",\n      \"method\": \"Drosophila genetics (loss-of-function, rescue experiments), in vitro/in vivo ubiquitination assays (mono-ubiquitination of Koi), immunofluorescence of LINC complex members\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic epistasis combined with biochemical ubiquitination assay and cross-species rescue, multiple orthogonal approaches\",\n      \"pmids\": [\"29689197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARIH1 is the E3 ubiquitin ligase that ubiquitinates PD-L1 following GSK3α-mediated phosphorylation at Ser279/Ser283, targeting PD-L1 for proteasomal degradation; ARIH1 overexpression suppresses tumor growth and promotes cytotoxic T cell activation in immunocompetent but not immunocompromised mice.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, ARIH1 overexpression/knockdown in tumor models, in vivo syngeneic tumor experiments, high-throughput drug screen\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and ubiquitination assay plus in vivo functional validation, single lab\",\n      \"pmids\": [\"33879767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARIH1 catalyzes mono-ISGylation of cGAS at K187, which promotes cGAS oligomerization and activation, thereby enhancing type I interferon and proinflammatory cytokine production in response to HSV-1 or cytoplasmic DNA; conditional Arih1 knockout mice are hypersensitive to HSV-1 and show reduced autoimmune phenotypes in TREX1-deficient background.\",\n      \"method\": \"Co-immunoprecipitation, ISGylation assays, ARIH1 KO/KD (siRNA, conditional mouse knockouts), HSV-1 infection models, site-directed mutagenesis (K187)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (biochemical ISGylation assay, mutagenesis at K187, conditional KO mouse models in two cell-type backgrounds), mechanistic and genetic validation converge\",\n      \"pmids\": [\"36217001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARIH1 ubiquitinates hnRNP-E1, promoting its degradation and thereby facilitating EMT induction; ARIH1 silencing increases hnRNP-E1 stability and reduces ubiquitination, delays EMT and invasion, while ARIH1 overexpression promotes EMT and invasion; ARIH1 silencing in breast cancer cells reduces cancer stem cell properties in vitro and tumor formation in vivo.\",\n      \"method\": \"Yeast two-hybrid (interaction identification), ARIH1 KD/OE in mammary epithelial and breast cancer cell lines, ubiquitination assays, miniTurboID proximity labeling, in vivo tumor formation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus ubiquitination assay plus KD/OE functional phenotype, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"35102251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The HHARI (ARIH1) Rcat (RING2) domain contains a di-aromatic surface that forms a binding platform for substrate recruitment (demonstrated for 4EHP); a phosphomimetic mutation on the auto-inhibitory Ariadne domain promotes Rcat release and reorientation enabling transthiolation and substrate modification, defining a general model for RBR substrate recognition.\",\n      \"method\": \"XL-MS, HDX-MS, NMR, biochemical binding and ubiquitination assays, phosphomimetic mutagenesis\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple structural/biophysical methods (XL-MS, HDX-MS, NMR) plus biochemical validation and mutagenesis, single lab\",\n      \"pmids\": [\"35716664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARIH1 mediates ubiquitination and proteasomal degradation of DNA-PKcs, thereby activating the STING pathway and promoting cytotoxic T cell infiltration; a phospho-mimetic mutant of cGAS (T68E/S213D) blocks this ARIH1-DNA-PKcs-STING signaling axis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, ARIH1 overexpression/knockdown, syngeneic in vivo tumor models, high-throughput drug screen\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and ubiquitination assay with in vivo validation, single lab\",\n      \"pmids\": [\"37429863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARIH1 catalyzes serine (oxyester) ubiquitylation in addition to canonical lysine (isopeptide) ubiquitylation on CRL-bound substrates; efficiency of Ser ubiquitylation is highly dependent on local sequence context; comprehensive mutagenesis of the Rcat domain identified residues differentially affecting oxyester vs. isopeptide bond formation.\",\n      \"method\": \"In vitro reconstitution with purified components, comprehensive active-site mutagenesis of Rcat domain, biochemical ubiquitylation assays measuring Ser vs. Lys ubiquitylation\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with systematic mutagenesis distinguishing Ser vs. Lys ubiquitylation activities, single lab but rigorous biochemistry\",\n      \"pmids\": [\"37870100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARIH1 interacts with SQSTM1/p62 and enhances RIG-I stability (via p62-mediated pathway), thereby promoting IFN-β and downstream ISG expression during influenza A virus infection; ARIH1 is upregulated during IAV infection.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, TCID50 viral titer assay, luciferase reporter assay, siRNA knockdown\",\n      \"journal\": \"Virology journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, co-IP plus reporter assay but mechanism of ARIH1 enzymatic action on RIG-I not directly established\",\n      \"pmids\": [\"37005687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"C. elegans ARI-1 (ARIH1 ortholog) functions as an RBR ubiquitin ligase with UBC-18 (ortholog of UbcH7) to control pharyngeal morphogenesis; genetic interactions show ARI-1 is the principal Ariadne family member for this process, and GFP reporters show dynamic expression in muscles and neurons.\",\n      \"method\": \"Yeast two-hybrid (ARI-1/UBC-18 interaction), C. elegans genetic analysis (double mutants, RNAi), GFP reporter expression\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in C. elegans plus yeast two-hybrid, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"16457801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In C. elegans, UBC-18 (UbcH7 ortholog)–ARI-1 (ARIH1 ortholog) complex acts in ubiquitin-mediated proteolysis to negatively regulate SUP-35 abundance, functioning redundantly with LIN-35/Rb (which acts as a transcriptional repressor of sup-35) to control pharyngeal morphogenesis; genetic suppressor analysis showed sup-35 mutations revert synthetic lethality of ubc-18; pha-1 double mutants.\",\n      \"method\": \"Genetic epistasis analysis, double/triple mutant analysis, molecular analysis of SUP-35 abundance\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with molecular validation of SUP-35 regulation, single lab, C. elegans ortholog\",\n      \"pmids\": [\"19521497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HHARI (ARIH1) localizes to both nucleus and cytoplasm, with higher nuclear levels; it co-localizes with Cajal bodies (p80 coilin, NOPP140), PML bodies, and SC35 bodies; ARIH1 knockdown causes reduced proliferation, increased apoptosis, G2 cell cycle arrest, and reduced total cellular RNA levels.\",\n      \"method\": \"Antibody-based immunofluorescence, RNAi knockdown screen, flow cytometry (cell cycle analysis), RNA quantification\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments with functional KD phenotype, multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"23059369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HHARI (ARIH1) binds many of the same substrate proteins as parkin (including CDCrel-1, synphilin-1, and CASK) in vitro, forms aggresomes morphologically indistinguishable from parkin-induced aggresomes (microtubule-dependent, containing ubiquitin-proteasome components), and is detected in human Lewy bodies in Parkinson's disease tissue.\",\n      \"method\": \"In vitro binding assays (pulldown), cell-based aggresome formation assays, immunofluorescence, immunohistochemistry of human brain tissue\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, in vitro pulldown plus cell morphology assay; no direct ubiquitination/enzymatic assay of specific substrates\",\n      \"pmids\": [\"21590270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARIH1 directly interacts with PHB1 via its RING1+RBR+RING2 domains and catalyzes K63-linked ubiquitination of PHB1 at K186; this modification promotes PHB1 phosphorylation by Akt and mitochondrial translocation of PHB1, maintaining mitochondrial stability and promoting oxidative phosphorylation in colorectal cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assays, site-directed mutagenesis (K186), subcellular fractionation, mitochondrial function assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus in vitro ubiquitination with site-directed mutagenesis, single lab\",\n      \"pmids\": [\"40285603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARIH1 independently ubiquitinates PD-L1 in vitro (without requiring CRL as scaffold) and also cooperates with CRLs to catalyze PD-L1 ubiquitination; phosphorylation of PD-L1 enhances ubiquitination by disrupting its membrane association (demonstrated using liposomes); NEDD4 family E3s also ubiquitinate PD-L1.\",\n      \"method\": \"In vitro reconstitution with purified components (ARIH1, CRL3SPOP, NEDD4), liposome-based enzymatic assays, phosphorylation-mimetic mutants\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified components and liposome assays providing mechanistic detail, single lab but rigorous biochemistry\",\n      \"pmids\": [\"40472843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARIH1 mediates ubiquitination and degradation of MFN2, promoting mitophagy and endoplasmic reticulum stress in trophoblasts under hypoxia/reoxygenation conditions; ARIH1 inhibition reverses suppressed proliferation/invasion and reduces ROS, and MFN2 inhibition abolishes the protective effects of ARIH1 downregulation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, ARIH1 KD/overexpression, in vivo PE rat model, HTR8 cell hypoxia/reoxygenation model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, co-IP and functional KD assays but mechanistic detail of ubiquitination site on MFN2 not fully established in abstract\",\n      \"pmids\": [\"40960900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARIH1 interacts with NCOA4 and promotes its K48-linked ubiquitination and proteasomal degradation, thereby suppressing ferritinophagy and ferroptosis in lung adenocarcinoma; ARIH1 loss results in iron accumulation, lipid peroxidation, glutathione depletion, and ferroptotic cell death.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays (K48-linkage), cycloheximide chase, siRNA knockdown, ferroptosis marker assays\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, co-IP plus ubiquitination assay but Tier 3 due to preprint-equivalent methods described in journal abstract without full structural/reconstitution data\",\n      \"pmids\": [\"42169065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARIH1 regulates learning and memory in mice by ubiquitinating and promoting degradation of GIRK2 in dorsal hippocampal CaMKII-expressing neurons; ARIH1 deficiency causes GIRK2 upregulation and spatial learning/memory deficits that are rescued by lentiviral ARIH1 restoration or GIRK channel inhibition; selective ARIH1 KD in CaMKII+ (but not PV+ or SST+) neurons recapitulates the memory deficit.\",\n      \"method\": \"ARIH1 heterozygous knockout mouse model, lentiviral ARIH1 rescue, cell-type-specific ARIH1 knockdown (CaMKII/PV/SST-Cre), ubiquitination assays, Morris water maze, novel object recognition, GIRK channel pharmacology\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO, cell-type-specific KD, lentiviral rescue, and ubiquitination assay converge, preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.03.10.625121\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HHARI (ARIH1) stimulates IFN-β secretion by directly targeting RIG-I in a neddylation-dependent manner; the acidic N-terminal/UBA-like domains of HHARI are essential for this pro-interferon activity and for interaction with neddylated cullins; truncated HHARI containing only the N-terminal domains retains neddylation-dependent interferon signaling; overexpression of cullins 1–5 enhances HHARI-mediated IFN-β secretion.\",\n      \"method\": \"HHARI truncation mutants, neddylation inhibitor experiments, overexpression of cullins, IFN-β secretion assays, RIG-I interaction studies\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single lab, functional assays with truncation mutants but no structural or reconstitution data; mechanism of direct RIG-I targeting not biochemically reconstituted\",\n      \"pmids\": [\"bio_10.1101_2025.02.01.636034\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARIH1 loss leads to MAP4 upregulation and microtubule stabilization (increased tubulin acetylation and enhanced spindle organization) in breast cancer cells, sensitizing them to paclitaxel; this identifies ARIH1 as a regulator of microtubule dynamics.\",\n      \"method\": \"ARIH1 siRNA knockdown in breast cancer cell lines, tubulin acetylation assays, MAP4 protein level measurement, paclitaxel sensitivity assays (viability, colony formation, apoptosis)\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, KD with downstream phenotype readouts but direct ARIH1 ubiquitination of MAP4 not biochemically demonstrated in abstract\",\n      \"pmids\": [\"40075632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Pyrotinib enhances interaction between ARIH1 and HER2, promoting HER2 ubiquitination and endocytosis leading to lysosomal degradation of HER2 in HER2-positive NSCLC; tumor growth suppression by pyrotinib in vivo is ARIH1-dependent.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, LC-MS/MS, in vivo xenograft tumor model with ARIH1 manipulation\",\n      \"journal\": \"Cellular oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, co-IP and ubiquitination assay plus in vivo pharmacology, but ARIH1 catalytic role on HER2 not reconstituted biochemically\",\n      \"pmids\": [\"41123818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Sec61β recruits ARIH1 and 4EHP to the mRNA 5' cap to inhibit eIF4E binding, resulting in selective translational repression of ER-targeted (ERpQC substrate) mRNAs during ER stress; Sec61β deficiency causes cytoplasmic aggresome formation due to overproduction of ERpQC substrates, and motor dysfunction in zebrafish that is rescued by exogenous ARIH1 expression.\",\n      \"method\": \"Co-immunoprecipitation (Sec61β–ARIH1–4EHP complex), mRNA cap-binding assays, Sec61β KD, zebrafish motor behavior rescue by ARIH1 overexpression, proteasome activity assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP establishing ternary complex, functional KD, and cross-species rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"41593190\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARIH1 (HHARI) is a RING-between-RING (RBR) E3 ubiquitin ligase that operates via a RING/HECT hybrid mechanism—binding its cognate E2 (UbcH7/UBE2L3) through RING1 (with a unique Zn2+-loop II that enforces an open E2~Ub conformation) and transferring ubiquitin via an obligate thioester intermediate at the RING2 active-site cysteine; it is activated by neddylated Cullin-RING ligase complexes, which relieve its autoinhibitory Ariadne domain and reorient the Rcat domain for substrate ubiquitination. ARIH1 ubiquitinates diverse substrates—including PD-L1, cGAS (mono-ISGylation at K187), 4EHP, DNA-PKcs, PHB1 (K63-linked), NCOA4 (K48-linked), MFN2, hnRNP-E1, HER2, and GIRK2—to regulate proteasomal or lysosomal degradation, mRNA translation arrest (via a Sec61β–ARIH1–4EHP complex at the 5' cap), innate immune signaling, nuclear architecture (mono-ubiquitination of the LINC complex component Koi), and ferroptosis suppression, while also catalyzing non-canonical serine (oxyester) ubiquitylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARIH1 (HHARI) is a RING-between-RING (RBR) E3 ubiquitin ligase that operates by a RING/HECT hybrid mechanism: it binds its cognate E2 (UbcH7/UbcH8) through its RING1 domain but transfers ubiquitin via an obligate thioester intermediate at a conserved catalytic cysteine in the RING2 (Rcat) domain, mechanistically distinguishing RBR ligases from canonical RING E3s [#0, #1]. Structural work explains each step of this cycle—the RING2 fold positions a single exposed catalytic cysteine in a near-mirror image of HECT active sites [#4], a unique Zn2+-loop II extension in RING1 acts as a steric wedge that enforces an open E2~Ub conformation favoring transthiolation [#6], and the Rcat domain presents a di-aromatic substrate-binding platform whose engagement is gated by release of the autoinhibitory Ariadne domain [#11]. ARIH1 is activated by neddylated Cullin-RING ligase (CRL) complexes, which stimulate its ligase activity and couple it to CRL-bound substrates [#3], and it can catalyze non-canonical serine (oxyester) ubiquitylation in addition to canonical lysine isopeptide linkages [#13]. Through this chemistry ARIH1 modifies a broad substrate repertoire to control distinct cellular outcomes: it ubiquitinates 4EHP to drive translational arrest under genotoxic stress and, with Sec61\\u03b2, assembles a 5' cap complex that selectively represses ER-targeted mRNA translation during ER stress [#5, #27]; it promotes proteasomal degradation of phosphorylated PD-L1 and of DNA-PKcs to enhance antitumor immunity [#8, #12]; it mono-ISGylates cGAS at K187 to potentiate innate immune signaling [#9]; and it mono-ubiquitinates the LINC-complex protein Koi to regulate nuclear positioning, a function shared and rescued across species [#7]. Patient-derived ARIH1 variants fail to rescue this conserved activity, linking the protein to developmental phenotypes [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing which E2 enzymes ARIH1 partners with defined the first step of its catalytic cycle and the specificity of RBR ligases.\",\n      \"evidence\": \"Yeast two-hybrid screen and in vitro binding assays mapping RING1/IBR interaction with UbcH7 and UbcH8\",\n      \"pmids\": [\"10521492\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not establish the catalytic mechanism of ubiquitin transfer\", \"No substrate identified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defining the minimal RING1-UbcH7 interaction surface and its requirement for a RING-HC architecture connected E2 selectivity to a structural determinant.\",\n      \"evidence\": \"Reciprocal co-IP, immunofluorescence co-localization, and point mutagenesis in mammalian cells\",\n      \"pmids\": [\"11278816\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of perinuclear localization not addressed\", \"Did not link binding to catalytic output\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolving how ARIH1 transfers ubiquitin reclassified it as a RING/HECT hybrid, answering whether RBR ligases use direct E2-to-substrate transfer or an enzyme thioester intermediate.\",\n      \"evidence\": \"In vitro ubiquitin transfer assays with active-site cysteine mutagenesis across RBR family members\",\n      \"pmids\": [\"21532592\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not explain how the open E2~Ub conformation is enforced\", \"Physiological substrates and activation unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery that neddylated CRLs bind and stimulate ARIH1 placed the enzyme into the cullin pathway and explained how a basally autoinhibited ligase is activated.\",\n      \"evidence\": \"Co-IP, in vitro auto-ubiquitylation, thioester discharge, activity-based probe reactivity, and in vivo CRL activity assays\",\n      \"pmids\": [\"24076655\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CRL-mediated activation not resolved\", \"Substrate range conferred by CRLs not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The RING2 NMR structure provided the structural rationale for the HECT-like catalytic cysteine arrangement.\",\n      \"evidence\": \"NMR solution structure of the HHARI RING2 domain with comparison to HECT ligase NEDD4\",\n      \"pmids\": [\"24058416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not capture the active conformation in context of full-length ligase\", \"Substrate-binding surface not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying 4EHP ubiquitination as a non-degradative output linked ARIH1 to translational control during genotoxic stress, extending its role beyond proteasomal targeting.\",\n      \"evidence\": \"RNAi with WT vs. catalytic-mutant rescue, ARIH1-4EHP co-IP, subcellular fractionation, and mRNA translation/viability assays\",\n      \"pmids\": [\"25624349\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site on 4EHP and chain type not defined\", \"Mechanism of ATM-mediated ARIH1 stabilization not detailed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Capturing the HHARI/UbcH7~Ub complex explained how RING1 promotes transthiolation rather than direct substrate ubiquitination.\",\n      \"evidence\": \"X-ray crystallography of the HHARI/UbcH7~Ub complex with mutagenesis and biochemical validation\",\n      \"pmids\": [\"28552575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address substrate recruitment to RING2\", \"Activation by CRLs not structurally integrated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that the conserved ortholog mono-ubiquitinates the LINC protein Koi defined a developmental, nuclear-positioning function and connected ARIH1 variants to phenotype via cross-species rescue.\",\n      \"evidence\": \"Drosophila loss-of-function and rescue genetics, ubiquitination assays, and immunofluorescence of LINC members\",\n      \"pmids\": [\"29689197\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific human disease entity not delineated in this work\", \"Whether Koi-equivalent regulation occurs in mammalian cells not shown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying ARIH1 as the E3 for phosphorylated PD-L1 connected it to immune checkpoint regulation and antitumor immunity.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, ARIH1 OE/KD in tumor models, syngeneic in vivo experiments, and drug screen\",\n      \"pmids\": [\"33879767\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dependence on CRL scaffolding not resolved here\", \"Direct vs. indirect catalysis not biochemically isolated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that ARIH1 mono-ISGylates cGAS at K187 established a non-ubiquitin modification activity driving innate immune activation.\",\n      \"evidence\": \"ISGylation assays, K187 mutagenesis, conditional Arih1 KO mice, and HSV-1/TREX1-deficient models\",\n      \"pmids\": [\"36217001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for ISG15 vs. ubiquitin transfer not defined\", \"How substrate choice between modifications is determined unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining the di-aromatic Rcat substrate platform and Ariadne-release gating produced a general model for how RBR ligases recruit and modify substrates.\",\n      \"evidence\": \"XL-MS, HDX-MS, NMR, and biochemical binding/ubiquitination assays with phosphomimetic mutagenesis\",\n      \"pmids\": [\"35716664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The physiological kinase relieving Ariadne autoinhibition not identified\", \"Generality across all substrates not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing ARIH1-mediated degradation of hnRNP-E1 linked the ligase to EMT and cancer stemness.\",\n      \"evidence\": \"Yeast two-hybrid, KD/OE in mammary cells, ubiquitination assays, miniTurboID, and in vivo tumor assays\",\n      \"pmids\": [\"35102251\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site and chain type on hnRNP-E1 not defined\", \"CRL dependence not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying DNA-PKcs as an ARIH1 degradation substrate connected the ligase to STING-pathway activation and T cell infiltration.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, ARIH1 OE/KD, syngeneic tumor models, and drug screen\",\n      \"pmids\": [\"37429863\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct catalysis vs. CRL recruitment not separated\", \"Ubiquitination site on DNA-PKcs not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating serine (oxyester) ubiquitylation expanded the chemical repertoire of ARIH1 beyond lysine isopeptide bonds and identified active-site residues controlling linkage chemistry.\",\n      \"evidence\": \"In vitro reconstitution with purified components and comprehensive Rcat-domain mutagenesis comparing Ser vs. Lys ubiquitylation\",\n      \"pmids\": [\"37870100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates of Ser ubiquitylation not identified\", \"Cellular relevance of oxyester linkages not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Reconstitution showed ARIH1 can ubiquitinate PD-L1 both independently and cooperatively with CRLs, and that substrate phosphorylation/membrane disengagement controls modification.\",\n      \"evidence\": \"In vitro reconstitution with purified ARIH1/CRL3SPOP/NEDD4 and liposome-based phosphomimetic assays\",\n      \"pmids\": [\"40472843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CRL-dependent vs. independent activity in cells unknown\", \"Cellular determinants of PD-L1 phosphorylation not addressed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying K63-linked ubiquitination of PHB1 connected ARIH1 to mitochondrial function via a non-degradative signal in colorectal cancer.\",\n      \"evidence\": \"Co-IP, in vitro ubiquitination, K186 mutagenesis, subcellular fractionation, and mitochondrial function assays\",\n      \"pmids\": [\"40285603\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How K63 linkage drives Akt phosphorylation of PHB1 mechanistically unclear\", \"CRL involvement not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Mouse genetics tied ARIH1-mediated degradation of GIRK2 to learning and memory in hippocampal CaMKII neurons.\",\n      \"evidence\": \"Heterozygous KO, cell-type-specific KD, lentiviral rescue, ubiquitination assays, and behavioral testing (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.10.625121\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not yet peer-reviewed\", \"Ubiquitination site on GIRK2 not mapped\", \"Direct catalysis vs. indirect regulation not isolated\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defining the Sec61\\u03b2-ARIH1-4EHP cap complex revealed how ARIH1 imposes selective translational repression of ER-targeted mRNAs during ER stress.\",\n      \"evidence\": \"Co-IP of the ternary complex, cap-binding assays, Sec61\\u03b2 KD, and ARIH1-rescued zebrafish motor phenotypes\",\n      \"pmids\": [\"41593190\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ARIH1 catalytic activity is required for repression not isolated here\", \"Substrate of ubiquitination within the complex not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ARIH1 selects among its many substrates and chooses between ubiquitin, ISG15, lysine vs. serine modification, and degradative vs. non-degradative chain types in a given cellular context remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking CRL identity to substrate choice\", \"Physiological signals gating Ariadne autoinhibition release not mapped\", \"Determinants of modification chemistry (Ub vs. ISG15, Lys vs. Ser) in cells unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 8, 9, 13]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 3, 6, 11, 13]},\n      {\"term_id\": \"GO:0031386\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 3, 8, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 9, 12]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [5, 27]}\n    ],\n    \"complexes\": [\"Sec61\\u03b2\\u2013ARIH1\\u20134EHP cap complex\", \"neddylated Cullin-RING ligase (CRL) complex\"],\n    \"partners\": [\"UBE2L3\", \"CUL1\", \"PHB1\", \"NCOA4\", \"SQSTM1\", \"SEC61B\", \"4EHP\", \"MFN2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":5,"faith_pct":80.0}}